Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "MoveOn"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Showing
1
-
8
of
8
Search:
'"MoveOn"'
,
query time: 0.03s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Obesity management interventions delivered in primary care for patients with osteoarthritis : a review of the clinical effectiveness
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... and men in the overweight category lost enough weight to
move
into the normal weight category, the risk...
”
Read Now
2
Obesity management interventions delivered in primary care for patients with osteoarthritis : a review of the clinical effectiveness
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... and men in the overweight category lost enough weight to
move
into the normal weight category, the risk...
”
Read Now
3
Pharmacoeconomic review report: Sodium zirconium cyclosilicate (Lokelma) (AstraZeneca Canada Inc.) : indication : for the treatment of hyperkalemia in adult patients.
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...The sponsor assumed that patients who started treatment on SZC would
move
on to BSC...
”
Read Now
4
Pharmacoeconomic review report: Sodium zirconium cyclosilicate (Lokelma) (AstraZeneca Canada Inc.) : indication : for the treatment of hyperkalemia in adult patients.
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...The sponsor assumed that patients who started treatment on SZC would
move
on to BSC...
”
Read Now
5
Blue light cystoscopy in patients with suspected non-muscle invasive bladder carcinoma: a review of clinical utility
by
Tran, Khai
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... or carcinoma in situ), Ta (raspberry growth on surface), and T1 (
moves
into submucosa layer) are those not yet...
”
Read Now
6
Blue light cystoscopy in patients with suspected non-muscle invasive bladder carcinoma: a review of clinical utility
by
Tran, Khai
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... or carcinoma in situ), Ta (raspberry growth on surface), and T1 (
moves
into submucosa layer) are those not yet...
”
Read Now
7
Pharmacoeconomic review report: Dolutegravir/Lamivudine (Dovato) (ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunodeficiency virus type1 (...
Published 2019
CADTH
Read Now
8
Pharmacoeconomic review report: Dolutegravir/Lamivudine (Dovato) (ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunodeficiency virus type1 (...
Published 2019
CADTH
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
610 - Medicine & health
4
330 - Economics
2
700 - The arts; fine & decorative arts
2
Language
English
8
Collection
National Center for Biotechnology Information
8
Author
Canadian Agency for Drugs and Technologies in Health
Severn, Melissa
2
Tran, Khai
2
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%22MoveOn%22&type=AllFields
Send by Email
×
Loading...